Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cell and Gene Therapy Catapult
Cell and Gene Therapy Catapult
Activities:
Manufacturing
Drug Delivery
Research & Development
Pharmaceutical
Cell & Gene Therapy
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Horiba joins cell & gene therapy manufacturing consortium
Headed by the Cell and Gene Therapy Catapult, the consortium comprises technology providers, pharmaceutical companies, therapy developers and charities
Regulatory
NHC named National Training Centre for UK skills initiative
The National Horizons Centre will provide hands-on training for advanced therapy medicinal products (ATMPs) and vaccine manufacture
Finance
Stevenage cell and gene therapy facility receives £3m government grant
The cell and gene therapy cluster around Stevenage has reportedly been recognised as a high potential opportunity zone, set to attract overseas investment to the
Regulatory
CGT Catapult analyses manufacturing and skills in cell and gene therapy
New data has shown cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector
Media
British cell and gene therapy accelerator releases annual report
The CGT Catapult has worked on more than 110 projects addressing industry challenges
Research & Development
CGT Catapult brings SMEs together
Fujifilm Diosynth, Eversheds Sutherland, Mathys & Squire and Stifel gather at CGT Catapult’s first UK Advanced Therapy Medicinal Products Investor Day
Research & Development
TCR2 Therapeutics and CGT Catapult join forces at UK Bioscience park
TCR<sup>2</sup> is the first US company to have a global development base at the Stevenage site, working with CGT Catapult to further its T cell therapies
Subscribe now